Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Aug 13;6(8):e1854. doi: 10.1038/cddis.2015.226

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2015 Macmillan Publishers Limited

Cell Death and Disease is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

TAT-spacer-GADD45β_60–86 peptide specifically prevents NMDA-induced MKK7 activation without interfering with MKK4 pathway. (a) Western blotting and relative quantification of P-MKK7/MKK7 ratio in 12 DIV cortical neurons treated with TAT-spacer-GADD45β_60–86 (5 μM), 100 μM NMDA, or the combination of the treatments for 5 (upper panel), 30 (middle panel) and 60 min (lower panel). Actin was used as loading control. Data are presented as mean±S.E.M. (two-way ANOVA, Tukey's post-hoc test, *P<0.05 CTR versus NMDA, ***P<0.001 CTR versus NMDA, ^#P<0.05 NMDA versus NMDA+MKK7I, ^##P<0.001 NMDA versus NMDA+MKK7I, n=6). (b) Western blotting and relative quantification of P-MKK4/MKK4 ratio in 12 DIV cortical neurons treated with TAT spacer-GADD45β_60-86 peptide (5 μM), 100 μM NMDA, or the combination of the treatments for 5 (upper panel), 30 (middle panel) and 60 min (lower panel). Actin was used as loading control. Data are presented as mean±S.E.M. (two-way ANOVA, interaction 40.05, n=6)

TAT-spacer-GADD45β_60–86 peptide specifically prevents NMDA-induced MKK7 activation without interfering with MKK4 pathway. (a) Western blotting and relative quantification of P-MKK7/MKK7 ratio in 12 DIV cortical neurons treated with TAT-spacer-GADD45β_60–86 (5 μM), 100 μM NMDA, or the combination of the treatments for 5 (upper panel), 30 (middle panel) and 60 min (lower panel). Actin was used as loading control. Data are presented as mean±S.E.M. (two-way ANOVA, Tukey's post-hoc test, *P<0.05 CTR versus NMDA, ***P<0.001 CTR versus NMDA, ^#P<0.05 NMDA versus NMDA+MKK7I, ^##P<0.001 NMDA versus NMDA+MKK7I, n=6). (b) Western blotting and relative quantification of P-MKK4/MKK4 ratio in 12 DIV cortical neurons treated with TAT spacer-GADD45β_60-86 peptide (5 μM), 100 μM NMDA, or the combination of the treatments for 5 (upper panel), 30 (middle panel) and 60 min (lower panel). Actin was used as loading control. Data are presented as mean±S.E.M. (two-way ANOVA, interaction 40.05, n=6)